Arch Biopartners has signed an agreement to buy a new diagnostic technology, which identifies irritable bowel syndrome (IBS).

The technology helps clinicians to diagnose IBS that causes frequent abdominal discomfort, pain and diarrhea.

Currently used IBS diagnosis tests which are time consuming are detected after the recognition of other conditions such as bowel cancer, inflammatory bowel disease, celiac disease and other infections.

The company said it will perform further validation studies and assess the commercial viability of the technology, as pre-conditions to exercising the option.